Leerink Partners analyst Geoff Porges maintained a Buy rating on Gilead Sciences (NASDAQ:GILD) on Monday, setting a price target of $74, which is approximately 7.79% above the present share price of $68.65.
Porges expects Gilead Sciences to post earnings per share (EPS) of $1.38 for the third quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Gilead Sciences, with an average price target of $79.1.
The analysts price targets range from a high of $100 to a low of $63.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $6.42 billion and a net profit of $2.95 billion. The company's market cap is $86.1 billion.
According to TipRanks.com, Leerink Partners analyst Geoff Porges is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.9% and a 49.75% success rate.
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.